Loading…
Jupiter Neurosciences, Inc. is projected to rise to $0.1083 by 2027, a +8% move from its current price of $0.10. JUNS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.0933 | $0.1001 | $0.1075 | +0.14% |
| Aug 6 | $0.0908 | $0.1003 | $0.1108 | +0.27% |
| Aug 7 | $0.0889 | $0.1004 | $0.1135 | +0.41% |
| Aug 8 | $0.0873 | $0.1005 | $0.1158 | +0.55% |
| Aug 9 | $0.086 | $0.1007 | $0.1179 | +0.68% |
| Aug 10 | $0.0848 | $0.1008 | $0.1198 | +0.82% |
| Aug 11 | $0.0838 | $0.101 | $0.1217 | +0.96% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.0838 | $0.101 | $0.1217 | +0.96% |
| Week 2 | $0.0783 | $0.1019 | $0.1327 | +1.93% |
| Week 3 | $0.0745 | $0.1029 | $0.1421 | +2.90% |
| Week 4 | $0.0715 | $0.1039 | $0.1509 | +3.89% |
| Week 5 | $0.0691 | $0.1049 | $0.1592 | +4.88% |
| Week 6 | $0.0671 | $0.1059 | $0.1672 | +5.89% |
| Week 7 | $0.0653 | $0.1069 | $0.1751 | +6.90% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company that engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements.
It researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. It is also involved in the commercialization and sale of GLO for skin beauty, MND for mental clarity, and PWR for energy, endurance, and muscle recovery under the Nugevia brand name. The company was formerly known as Jupiter Orphan Therapeutics, Inc.
and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.
Jupiter Neurosciences, Inc. trades under the symbol JUNS. The current price is $0.09 with a market cap of $4.34M and a rank of 5315." The forecast shows a mixed price path with some years in neutral territory and several longer-term bullish periods, including notable upside in the 2032-2050 horizon.
A major floor 10.0% below — a decisive break under it would weaken the trend.
The nearest floor, 10.0% below — buyers have tended to step in here.
The nearest ceiling, 180.0% above — a clean break opens room to run.
A major ceiling 365.0% above — clearing it would confirm fresh momentum.
Key JUNS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of JUNS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.1022 | Sell | $0.1048 | Sell |
| MA 10 | $0.1295 | Sell | $0.124 | Sell |
| MA 20 | $0.1598 | Sell | $0.1524 | Sell |
| MA 50 | $0.2082 | Sell | $0.2141 | Sell |
| MA 100 | $0.293 | Sell | $0.3358 | Sell |
| MA 200 | $0.6575 | Sell | $0.6654 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 20.76 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -139.44 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -49.72 | Sell |
| Bollinger %B (20,2) | 0.05 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.95 | Sell |
| Awesome (5,34) | -0.09 | Sell |
| Ultimate (7,14,28) | 6.83 | Buy |
| Momentum (10) | -0.08 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 0.08 | Buy |
| ADX (14) | 35.37 | Sell |
| ATR (14) | 0.01 | Info |
The 30-day technical picture is NEUTRAL with an RSI of 20. The 50-day simple moving average is $0.2082 and the 200-day simple moving average is $0.6575. The near-term structure has a defined support at $0.09 and a resistance at $0.28.
The thirty-day range spans from a low of $0.0565 to a high of $0.1432, indicating a broad fluctuation around the current price. Annualized volatility is 100%, signaling substantial movement potential in the short run.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.09 | $0.10 | $0.1468 | 0% | Neutral | |
| $0.0789 | $0.1083 | $0.1606 | +8% | Neutral | |
| $0.0589 | $0.086 | $0.136 | -14% | Neutral | |
| $0.0574 | $0.0883 | $0.1469 | -12% | Neutral | |
| $0.053 | $0.0856 | $0.1481 | -14% | Neutral | |
| $0.059 | $0.0995 | $0.1783 | -1% | Neutral | |
| $0.0708 | $0.1246 | $0.2303 | +25% | Bullish | |
| $0.0678 | $0.1243 | $0.2362 | +24% | Bullish | |
| $0.0639 | $0.1218 | $0.2373 | +22% | Bullish | |
| $0.0518 | $0.1025 | $0.2045 | +3% | Neutral | |
| $0.0668 | $0.1485 | $0.3256 | +48% | Bullish | |
| $0.1448 | $0.3218 | $0.7401 | +222% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.09 | $0.10 | $0.1231 | +0.00% |
| September 2026 | $0.0888 | $0.1079 | $0.1368 | +7.89% |
| October 2026 | $0.0919 | $0.1132 | $0.1465 | +4.95% |
| November 2026 | $0.0881 | $0.1098 | $0.1444 | -3.00% |
| December 2026 | $0.0874 | $0.1101 | $0.1468 | +0.19% |
Click any year to see its month-by-month JUNS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, JUNS could reach as high as $0.1468, with a base case around $0.10 and support toward $0.09 — roughly 0% from $0.10. A consolidation phase looks the most probable path here.
Expect JUNS to range from $0.0789 to $0.1606 through 2027. The $0.1083 average target implies a +8% move from current prices. That is up +8% on the projected 2026 average. Price action looks broadly range-bound.
The JUNS price prediction for 2028 points to an average of $0.086 (low $0.0589, high $0.136) — a potential decline of -14% on today's $0.10. A consolidation phase looks the most probable path here.
In 2029, JUNS is projected to trade between $0.0574 and $0.1469, averaging $0.0883 — a potential decline of -12% from today's $0.10. That is up +3% on the projected 2028 average. Price action looks broadly range-bound.
Jupiter Neurosciences, Inc.'s 2030 outlook centres on $0.0856, within a $0.053 to $0.1481 range. That is -3% versus the projected 2029 average. That marks a -14% change versus current levels. A consolidation phase looks the most probable path here.
By 2031, JUNS could reach as high as $0.1783, with a base case around $0.0995 and support toward $0.059 — roughly -1% from $0.10. Price action looks broadly range-bound.
Expect JUNS to range from $0.0708 to $0.2303 through 2032. The $0.1246 average target implies a +25% move from current prices. That is up +25% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The JUNS price prediction for 2033 points to an average of $0.1243 (low $0.0678, high $0.2362) — a potential gain of +24% on today's $0.10. Momentum favours further upside here.
In 2034, JUNS is projected to trade between $0.0639 and $0.2373, averaging $0.1218 — a potential gain of +22% from today's $0.10. That is -2% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
Jupiter Neurosciences, Inc.'s 2035 outlook centres on $0.1025, within a $0.0518 to $0.2045 range. That is -16% versus the projected 2034 average. That marks a +3% change versus current levels. Price action looks broadly range-bound.
By 2040, JUNS could reach as high as $0.3256, with a base case around $0.1485 and support toward $0.0668 — roughly +48% from $0.10. Buyers look set to stay in control over this stretch.
Expect JUNS to range from $0.1448 to $0.7401 through 2050. The $0.3218 average target implies a +222% move from current prices. That is up +117% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in JUNS today (≈ 10,000 JUNS) could be worth
$3,217.96
+$2,217.96 (+222%) by 2050 · US Dollar
Based on the average projected JUNS price of $0.32 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in JUNSwould be worth at today's price.
$1,000 invested in JUNS on Jul 31, 2025 (≈ 714.285726 JUNS) would be worth
$71.43
-$928.57 (-92.9%) today · 0.07× · US Dollar
Based on a JUNS entry price of $1.4 vs. today's $0.1.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.121 | $826.45 | -17.4% |
| 1 month ago | $0.215 | $465.12 | -53.5% |
| 3 months ago | $0.39 | $256.41 | -74.4% |
| 6 months ago | $0.59 | $169.49 | -83.1% |
| 1 year ago | $1.4 | $71.43 | -92.9% |
| All time (1.7y) ago | $5.49 | $18.21 | -98.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our JUNS forecast.
Our base-case forecast reaches $0.20 around 2050.
Implied market cap at $0.20: $9.64M
2032–2034 show a bullish tilt, with 2032 posting an average of $0.1124, a max of $0.2078, ROI of 24.9%, and sentiment BULLISH; 2033 posting an average of $0.1119, a max of $0.2127, ROI of 24.4%, and sentiment BULLISH; 2034 posting an average of $0.1093, a max of $0.213, ROI of 21.4%, and sentiment BULLISH.
2035 remains NEUTRAL with an average price of $0.0924, a min of $0.0467, a max of $0.1844, and ROI of 2.7%.
2040 moves into a BULLISH phase with an average of $0.1334, a min of $0.0600, a max of $0.2926, and ROI of 48.2%.
2050 shows a strong long-term upturn with an average of $0.2902, a min of $0.1306, a max of $0.6674, and ROI of 222.4%, continuing the BULLISH sentiment.
Tap a question to reveal the answer.
The forecast for 2030 shows min $0.0478, avg $0.077, max $0.1334, ROI -14.4%, sentiment NEUTRAL.
The forecast is mixed. Years like 2032 (avg $0.1124, max $0.2078, ROI 24.9%, sentiment BULLISH), 2033 (avg $0.1119, max $0.2127, ROI 24.4%, sentiment BULLISH), and 2034 (avg $0.1093, max $0.213, ROI 21.4%, sentiment BULLISH) show upside potential, while nearer-term years such as 2028 (avg $0.0771, ROI -14.3%), 2029 (avg $0.0797, ROI -11.4%), and 2030 (avg $0.077, ROI -14.4%) reflect risk and downside scenarios.
The 2050 forecast shows a max price of $0.6674 and an average of $0.2902, with a min of $0.1306. Reaching $0.50 would be below the forecast max, but these figures are not guaranteed.
The 30-day range is $0.0565-$0.1432 with support at $0.09 and resistance at $0.28. RSI14 is 20, SMA50 is $0.2082, SMA200 is $0.6575, and annualized volatility is 100%.
Current price is $0.09 and market cap is $4.34M; the asset is ranked 5315.
Jupiter Neurosciences, Inc. Community Discussion
0Share your Jupiter Neurosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.